QuidelOrtho Q2 revenue $665M, GAAP loss $(0.80)/share, adj. EPS $0.26; respiratory revenue down 74%

QuidelOrtho Corp

2023-Q2 EPS reported -$0.07 revenue$1,511,200,000

Revenue $665.1M (+8% reported) but down 26% on supplemental combined basis vs Q2 2022.
GAAP diluted loss per share $(0.80); adjusted EPS $0.26 vs $2.12 supplemental combined prior year.
Non-respiratory revenue +3% supplemental combined; Labs unit +9% constant currency; respiratory -74%.
Paid down $72M on Term Loan (excess $20M) and final $40M for Alere Cardiometabolic acquisition.
Completed Savanna EUA and 510(k) FDA submissions as planned.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

QuidelOrtho Corp reported the second quarter ended July 2, 2023 results: revenue $665.1 million.

Period: the second quarter ended July 2, 2023
Revenue: $665.1 million
Result: reported results

Exact text from the filing

today announced financial results for the second quarter ended July 2, 2023. The Company reported total revenue for the second quarter of 2023 of $665.1 million, compared to $613.4 million for the second quarter of 2022. GAAP diluted loss per share (LPS) for the second quarter of 2023 decreased to $(0.80), compared to diluted EPS of $0.36 for the second quarter of 2022.

View on SEC.gov

Browse all earnings releases →

QuidelOrtho Corp filing history →

Source: SEC EDGAR

accession 0001906324-23-000044

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.